Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0044-1786364
Original Article

Mutational Profiling by Next-Generation Sequencing in Patients with Metastatic Non-Small Cell Lung Carcinoma: Our Experience

Hitesh Deka
1   Department of Medical Oncology, Tirunelveli Medical College and Hospital, Tirunelveli, Tamil Nadu, India
,
Neelakshi Mahanta
2   Department of Medical Oncology, State Cancer Institute, Guwahati, Assam, India
,
Naba Kumar Kalita
3   Department of Biochemistry, Kokrajhar Medical College, Kokrajhar, Assam, India
,
Bibhash Chandra Goswami
4   Department of Radiation Oncology, State Cancer Institute, Guwahati, Assam, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Hitesh Deka

Introduction According to GLOBOCAN 2020, overall lung cancer is the second most common cancer in both sexes (11.4%) accounting for highest cancer-related mortality (18%).[1] Adenocarcinoma subtype of non-small cell lung cancer (NSCLC) is the most common subtype and is divided into further molecular subtypes based on oncogenic driver mutations. Overall survival in these patients is poor with the use of conventional platinum-based double chemotherapy and various recent studies on targeted therapy studies have showed improved survival. Therefore, broad panel-based testing like next-generation sequencing (NGS) is strongly recommended to identify these targetable driver mutations.

Aims and Objectives The aim of this study was to evaluate the mutational profile in patients with metastatic NSCLC (mNSCLC) by NGS method.

Materials and Methods A hospital-based prospective observational study done on 88 patients under the Department of Medical Oncology, State Cancer Institute during a period of 1 year. All patients above 18 years of age diagnosed as mNSCLC having Eastern Cooperative Oncology Group performance status 0 to 2 and evaluated for mutational profiling by NGS method were included. Five gene panel tests including endothelial growth factor receptor (EGFR), echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (EML4-ALK), BRAF, mesenchymal epithelial transition (MET), and ROS proto-oncogene 1 (ROS1) were used.

Results and Observations Majority of mNSCLC cases were in the age group of 41 to 50 years (n = 30, 34.1%) with average age at presentation being 53.74 years. Male: female ratio was 1.14:1 and most patients were nonsmokers. Adenocarcinoma subtype of mNSCLC cases had the highest mutational burden (n = 55, 62.5%). EGFR (n = 32, 56.14%) was the most common mutation followed by EML4-ALK (n = 19, 33.33%). Most common EGFR mutation was in Exon 19. Other rare mutations were ROS1 (n = 4), BRAF V600E (n = 1), and MET (n = 1). Skeleton was the most common site of metastasis across all driver mutations.

Conclusion EGFR and EML4-ALK were the commonest targetable mutations detected in the study. As there is very limited data from North Eastern region of India regarding mutational status in mNSCLC, this study opens up possibilities for further studies targeting multiple mutations to give us more comprehensive understanding of the mutational landscape of mNSCLC in this era of precision medicine.

Keywords

EGRF - EML4-ALK - lung cancer - NGS - oncogenic driver mutations


Publication History

Received: 13 August 2023

Accepted: 24 March 2024

Article published online:
23 April 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Google Scholar
  • 2 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer Statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6: 1063-1075
    CrossrefPubMedGoogle Scholar
  • 3 Schiller JH, Harrington D, Belani CP. et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 (02) 92-98
    CrossrefPubMedGoogle Scholar
  • 4 Lindeman NI, Cagle PT, Beasley MB. et al; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. [published correction appears in J Mol Diagn. 2013 Sep;15(5):730] J Mol Diagn 2013; 15 (04) 415-453
    CrossrefPubMedGoogle Scholar
  • 5 Lim C, Tsao MS, Le LW. et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol 2015; 26 (07) 1415-1421
    CrossrefPubMedGoogle Scholar
  • 6 Gutierrez ME, Choi K, Lanman RB. et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer 2017; 18 (06) 651-659
    CrossrefPubMedGoogle Scholar
  • 7 Aisner DL, Railey GJ. Non–small cell lung cancer: recommendations for biomarker testing and treatment. J Natl Compr Canc Netw 2021; 19 (05) 610-613
    CrossrefGoogle Scholar
  • 8 Chun YJ, Choi JW, Hong MH. et al; Korean Lung Cancer Consortium (KLCC). Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. PLoS One 2019; 14 (11) e0224379
    CrossrefPubMedGoogle Scholar
  • 9 Zhang Y, Shen WX, Zhou LN. et al. The value of next-generation sequencing for treatment in non-small cell lung cancer patients: the observational, real-world evidence in China. BioMed Res Int 2020; 2020: 9387167
    PubMedGoogle Scholar
  • 10 Facchinetti F, Tiseo M, Di Maio M. et al. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res 2016; 5 (03) 301-321
    CrossrefPubMedGoogle Scholar
  • 11 Fernandes MGO, Jacob M, Martins N. et al. Targeted gene next-generation sequencing panel in patients with advanced lung adenocarcinoma: paving the way for clinical implementation. Cancers (Basel) 2019; 11 (09) 1229
    CrossrefPubMedGoogle Scholar
  • 12 Reis D, Marques C, Dias M, Campainha S, Cirnes L, Barroso A. Mutational profile of non-small cell lung cancer patients: use of next-generation sequencing. Pulmonology 2020; 26 (01) 50-53
    CrossrefPubMedGoogle Scholar
  • 13 Rana V, Ranjan P, Jagani R, Rathi KR, Kumar D, Khera A. A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: a clinical and epidemiological study. Med J Armed Forces India 2018; 74 (02) 148-153
    CrossrefPubMedGoogle Scholar
  • 14 Rosell R, Moran T, Queralt C. et al; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361 (10) 958-967
    CrossrefPubMedGoogle Scholar
  • 15 Mohan A, Garg A, Gupta A. et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020; 37 (03) 190-197
    CrossrefPubMedGoogle Scholar
  • 16 Doval D, Prabhash K, Patil S. et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Ther 2015; 8: 117-123
    Google Scholar